Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression

Clinical Pharmacokinetics

Volumn 41, Issue 11, 2002, Pages 853-876

  Ulrich, Sven ^a   Läuter, Jürgen ^b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DRUG METABOLITE; NORTRIPTYLINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; COVARIANCE; DATA ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; HUMAN; LOGISTIC REGRESSION ANALYSIS; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SIDE EFFECT;

EID: 0036378713     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241110-00004     Document Type: Review

References (83)

1. Asberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971;4:331-4
2. Burrows GD, Davies B, Scoggins BA. Plasma concentrations of nortriptyline and clinical response in depressive illness. Lancet 1972; II: 619-23
3. Orsulak PJ. Therapeutic drug monitoring of antidepressants: guidelines updated. Ther Drug Monit 1989; 11: 497-507
4. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: principles and practice. Psychopharmacology 1993; 16: 611-41
5. Balant-Gorgia EA, Balant LP. Therapeutic drug monitoring: relevance during the drug treatment of psychiatric disorders. CNS Drugs 1995; 3 (6): 432-53
6. Braithwaite R, Goulding T, Theano G, et al. Plasma concentration of amitriptyline and clinical response. Lancet 1972: II: 1297-300
7. Coppen A, Ghose K, Montgomery S, et al. Amitriptyline plasma concentration and clinical effect. Lancet 1978; 14: 63-6
8. Glassman AH, Schildkraut JJ, Orsulak PJ, et al. Tricyclic antidepressants, blood level measurements and clinical outcome: an APA task force report. Am J Psychiatry 1985; 142: 155-62
9. Kuss HJ, Jungkunz G, Holsbör F. Amitriptyline: looking through the therapeutic window. Lancet 1984; I: 464-5
10. Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13: 381-92
11. Perry PJ, Zeilmann C, Amdt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230-40
12. Grohmann R, Rüther E, Engel RR, et al. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatria 1999; 32: 21-8
13. Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport 1998. Berlin: Springer, 1998: 455-78
14. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatry 2000; 177: 292-302
15. Barbui C, Hotopf M. Amitriptyline vs the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001; 178: 129-44
16. Ulrich S, Wurthmann C, Brosz M, et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia: a review. Clin Pharmacokinet 1998; 34: 227-63
17. Quitkin FM, Rabkin JG, Gerald J, et al. Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157: 327-37
18. Medawar C. The antidepressant web. Int J Risk Saf Med 1997; 10: 75-126
19. Medical Research Council Clinical Psychiatry Committee. Clinical trial of the treatment of depressive illness. BMJ 1965; 1: 881-6
20. Baumann P, Jonzier-Perey M, Koeb L, et al. Amitriptyline pharmacokinetics and clinical response: metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1: 102-12
21. Breyer-Pfaff U, Gaertner HJ, Giedke H. Plasma levels, psychophysiological variables, and clinical response to amitriptyline. Psychiatr Res 1982; 6: 223-34
22. Breyer-Pfaff U, Gaertner HJ, Kreuter F, et al. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 1982; 76: 240-4
23. Breyer-Pfaff U, Giedke H, Gaertner HJ, et al. Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J Clin Psychopharmacol 1989; 9: 116-21
24. Butch JE, Ahmed O, Hullin RP, et al. Antidepressive effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. Psychopharmacology 1988; 94: 197-205
25. Coppen A, Ghose K, Jorgensen A. Pharmacokinetics and pharmacodynamics of amitriptyline in depression. Prog Neuropsychopharmacol 1979; 3: 191-9
26. Click MA, Zisook S. Amoxapine and amitriptyline: serum levels and clinical response in patients with primary unipolar depression. J Clin Psychiaty 1982; 43: 369-71
27. Cournoyer G, De Montigny C, Ouellette J, et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 1987; 7: 385-93
28. Corona GL, Fenoglia L, Pinelli P, et al. Amitriptyline and nortriptyline plasma levels and therapeutic response in depressed women. Pharmacopsychiatria 1977; 10: 299-308
29. Corona GL, Pinelli P, Zerbi F, et al. Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders. Pharmacopsychiatria 1980; 13: 102-10
30. Corona GL, Zerbi F, Pinelli P, et al. Amitriptyline and nortriptyline plasma levels monitoring: perspective in clinical practice. Commun Psychopharmacol 1980; 4: 309-16
31. Corona GL, Cucchi ML, Fratini P, et al. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression. Psychopharmacology 1990; 100: 334-8
32. Edelbroek PM, Zitman FG, Schreuder JN, et al. Amitriptyline metabolism in relation to antidepressant effect. Clin Pharmacol Ther 1984; 35: 467-73
33. Galuszko P, Jakitowicz J, Landowski J, et al. Plasma amitriptyline levels and its therapeutic effect in endogenous depression. Psychiar Pol 1987; 21: 110-4
34. Garaj V, Frank V, Drimalova M, et al. Relation of plasma amitriptyline and nortriptyline levels to the therapeutic response in endogenous depression. Cesk Psychiatr 1986; 82: 307-12
35. Jakitowicz J. The amitriptyline plasma levels and therapeutic response in patients with affective illness. Psychiat Pol 1991; 25: 14-20
36. Jungkunz G, Kuß HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients. Pharmakopsychiatr 1980; 13: 111-6
37. Kocsis JH, Hanin I, Bowden C, et al. Imipramine and amitriptyline plasma concentrations and clinical response in major depression. Br J Psychiatry 1986; 148: 52-7
38. Kupfer DJ, Hanin I, Spiker D, et al. Amitriptyline plasma levels and clinical response in primary depression: II. Commun Psychopharmacol 1978; 2: 441-50
39. Leclerc P, Carrier G, Billon B, et al. Tricyclic antidepressant plasma levels monitoring in daily practice: the Sherbrooke experience [abstract]. Clin Biochem 1983; 16: 118
40. Lehmann LS, Bowden CL, Redmont FC, et al. Amitriptyline and nortriptyline response profiles in unipolar depressed patients. Psychopharmacology 1982; 77: 193-7
41. Liisberg P, Mose H, Amdisen A, et al. A clinical trial comparing sustained release amitriptyline (Amitriptyline, retard) and conventional amitriptyline tablets (Amitriptylin) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortriptyline. Acta Psychiatr Scand 1978; 57: 426-35
42. Liu P. Relation of plasma levels and clinical response to amitriptyline in treating endogenous depression. Chin J Neurol Psychiatry 1988; 21: 263-6
43. Loudon JB, Tiplady B, Ashcroft GW, et al. Zimelidine and amitriptyline in the treatment of depressive illness in general practice. Acta Psychiatr Scand Suppl 1981; 290: 454-63
44. Mendlewicz J, Linkowski P, Rees JA. A double-blind comparison of dothiepin and amitriptylin in patients with primary. affective disorder: serum levels and clinical response. Br J Psychiatry 1980; 136: 154-60
45. Miljkovic B, Pokrajac M, Timotijevic I, et al. Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients. Eur J Drug Metab Pharmacokinet 1996; 21: 251-5
46. Monteleone P, Fabrazzo M. Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients. Pharmacopsychiatry 1994; 27: 238-41
47. Montgomery SA, McAuley R, Rani SJ, et al. Amitriptyline plasma concentrations and clinical response. BMJ 1979; 27: 230-1
48. Montgomery SA, McAuley R, Montgomery DB, et al. Pharmacokinetics and efficacy of maprotiline and amitriptyline in endogenous depression: a double-blind controlled trial. Clin Ther 1980; 3: 292-310
49. Moyes IC, Ray RL, Moyes RB. Plasma levels and clinical improvement: a comparative study of clomipramine and amitriptyline in depression. Postgrad Med J 1980; 56 Suppl. 1: 127-9
50. Olig RM, Staton RD, Beatty WW, et al. Antidepressant treatment of children: clinical relapse is unrelated to tricyclic plasma concentrations. Percept Mot Skills 1985; 60: 879-89
51. Pidrman V, Krpalek P. Levels of amitriptyline and its metabolism in the treatment of depression. Cesk Psychiatr 1991; 87: 209-18
52. Quednow B, Walter H, Genz A, et al. Amitriptyline levels and clinical effects. Agressologie 1981; 22: 15-8
53. Rao ML, Deister A, Laux G, et al. Low serum levels of tricyclic antidepressants in amitriptyline and doxepin treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatria 1996; 29: 97-102
54. Rickels K, Weise C, Case G, et al. Tricyclic plasma levels in depressed outpatients treated with amitriptyline. Psychopharmacology 1983; 80: 14-8
55. Robinson DS, Cooper TB, Ravaris CL, et al. Plasma tricyclic drug levels in amitriptyline-treated depressed patients. Psychopharmacology 1979; 63: 223-31
56. Robinson DS, Cooper TB, Howard D, et al. Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J Clin Psychopharmacol 1985; 5: 83-8
57. Rowan PR, Paykel ES, Marks V, et al. Serum levels and response to amitriptyline in depressed out-patients. Neuropsychobiology 1984; 12: 9-15
58. Schnyder C, Baumann P, Jonzier-Perey M, et al. Use of amitriptyline in low dose in gerontopsychiatry. Schweiz Med Wochenschr 1985; 115: 1128-34
59. Shimoda K, Yasuda S, Morita S, et al. Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Psychiatry Clin Neurosci 1997; 51: 35-41
60. Ulrich S, Northoff G, Wurthmann C, et al. Serum levels of amitriptyline and therapeutic effect in non-delusional moderate to severely depressed in-patients: a therapeutic window relationship. Pharmacopsychiatria 2001; 34: 33-40
61. Vandel S, Vandel B, Sandoz M, et al. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol 1978; 14: 185-90
62. Gurney C, Roth M, Garside RF, et al. Studies in the classification of affective disorders. Br J Psychiatry 1972; 121: 162-6
63. Vandel S, Vandel B, Allers G, et al. Interaction between Amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response. Psychopharmacology 1979; 65: 187-90
64. Zhang X. Serum concentrations of amitriptyline and its metabolites and clinical effect in depressive patients. Chin J Neurol Psychiatry 1992; 25: 196-8
65. Ziegler VE, Clayton PJ, Biggs JT. A comparison study of amitriptyline and nortriptyline with plasma levels. Arch Gen Psychiatry 1977; 34: 607-12
66. D'Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther 1995; 58: 605-15
67. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-4
68. Ziegler VE, Meyer DA, Rosen SH, et al. Amitriptyline dosage schedule, sampling time and tricyclic plasma levels. Br J Psychiatry 1977; 131: 168-71
69. Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982; 15: 56-61
70. Wallace JE, Hamilton HE, Goggin LK, et al. Determination of amitriptyline at nanogram levels in serum by electron capture gas-liquid chromatography. Anal Chem 1975; 47: 1516-9
71. Mould GP, Stout G, Aherne GW, et al. Radioimmunoassay of amitriptyline and nortriptyline in body fluids. Ann Clin Biochem 1978; 15: 221-5
72. Rao ML, Staberock U, Baumann P, et al. Monitoring tricyclic antidepressant concentration in serum by FPIA compared with GC and HPLC. Clin Chem 1994; 40: 929-33
73. Davis JM, Wang Z. Power analysis for correlation of plasma level and clinical data. In: Gram LF, Balant LP, Meltzer HY, et al., editors. Clinical pharmacology in psychiatry. Berlin: Springer, 1993: 253-64
74. Stolley PD, Strom BL. Sample size calculations for clinical pharmacological studies. Clin Pharmacol Ther 1986; 39: 489-90
75. Preskorn SH. Factors affecting the biphasic concentration: effect relationships of tricyclic antidepressants. In: Dahl S, Usdin E, editors. Clinical pharmacology-in psychiatry. London: McMillan, 1981: 297-306
76. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991; 52 Suppl. 6: 23-33
77. Meador-Woodruff JH, Akil M, Wisner-Carlson R, et al. Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels. J Clin Psychopharmacol 1988; 8: 28-32
78. Meador-Woodruff JH, Grunhaus L. Profound behavioral toxicity due to tricyclic antidepressants. J Nerv Ment Dis 1986; 174: 628-30
79. Janicak PG, Javaid JI, Davis JM. Neuroleptic plasma levels: methodological issues, study design, and clinical applicability. In: Marder SR, Davis JM, Janicak PG, editors. Clinical use of neuroleptic plasma levels. Washington: Am Psych Press, 1993: 17-44
80. Teicher MH, Baldessarini RJ. Selection of neuroleptic dosage. Arch Gen Psychiatry 1985; 42: 636-7
81. Hirschfeld RMA. Psychosocial predictors of outcome in depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the 4th generation of progress. New York: Raven, 1995: 1113-21
82. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
83. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999; 174: 297-303